Evaluation of the Safety and Effectiveness of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) for the Prevention of Itching Associated With Allergic Conjunctivitis: A Postmarketing Surveillance Study in Korea
Evaluation of the Safety and Effectiveness of Lastacaft® Ophthalmic Solution 0.25% (Alcaftadine) for the Prevention of Itching Associated With Allergic Conjunctivitis: A Postmarketing Surveillance Study in Korea
This post-marketing surveillance study will assess the safety and efficacy of Lastacaft® Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea.
Inclusion Criteria:
-Patients with itching associated with allergic conjunctivitis.
Exclusion Criteria:
-Patients with hypersensitivity to Lastacaft® or its components.
Chungcheongnam-do, 31151, South Korea
Daejoen, 35015, South Korea
Daejoen, 35365, South Korea
Geyonggi-do, 11695, South Korea
Geyonsangnam-do, 51356, South Korea
Gyeongsangnam-do, 50621, South Korea
Gyeongsangnam-do, 51408, South Korea
Gyeongsangnam-do, 51436, South Korea
Haeundae-gu, 48064, South Korea
Jeollabuk-do, 54921, South Korea
Jeollabuk-do, 5492, South Korea
Jeollabuk-do, 54972, South Korea
Jeollanam-do, 57643, South Korea
Kyounggi-do, 410719, South Korea